These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 24659374)

  • 21. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
    Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis.
    Zhang J; Li J; Zhu C; Song Y; Xia F; Ma X
    Drug Des Devel Ther; 2017; 11():3235-3244. PubMed ID: 29180848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
    Piwko C; Prady C; Yunger S; Pollex E; Moser A
    Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T; Teuwen LA; Rutten A; Dirix L
    Expert Opin Biol Ther; 2015 May; 15(5):749-60. PubMed ID: 25865453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
    Gonçalves A; Trédan O; Villanueva C; Dumontet C
    Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.
    Peddi PF; Hurvitz SA
    Future Oncol; 2013 Mar; 9(3):319-26. PubMed ID: 23469968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
    N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
    Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
    Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
    Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
    Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
    J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
    Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
    Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab emtansine: mechanisms of action and drug resistance.
    Barok M; Joensuu H; Isola J
    Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Baselga J; Lewis Phillips GD; Verma S; Ro J; Huober J; Guardino AE; Samant MK; Olsen S; de Haas SL; Pegram MD
    Clin Cancer Res; 2016 Aug; 22(15):3755-63. PubMed ID: 26920887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
    J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
    Perez EA; Hurvitz SA; Amler LC; Mundt KE; Ng V; Guardino E; Gianni L
    Breast Cancer Res; 2014 May; 16(3):R50. PubMed ID: 24887458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
    Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
    Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.